Zobair Younossi, MD, MPH1, Marcelo Kugelmas, MD1, Kimberly A.. Brown, MD2, Christina J. Hanson, FNP-C3, Christina Hanson, MD4, Brian Lam, PA-C1, Fatema Nader, MBBS1, Samantha H.. Scalici, MBA5, Gregory D. Salinas, PhD6, Christa Perry, MS7 1The Global NASH Council, Washington, DC; 24. Division of Gastroenterology and Hepatology, Henry Ford Health,, Detroit, MI; 3South Denver GI, Englewood, NJ; 4South Denver Gastroenterology, Denver, CO; 5CE Outcomes LLC, Birmingham, AL; 6CE Outcomes, LLC, Birmingham, AL; 7Chronic Liver Disease FoundationMS, Clark, NJ Introduction: MASH is the most prevalent chronic liver disease, contributing to mortality, morbidity, and economic burden. However, despite the substantial impact of this disease, the emergence of new biomarkers, promising treatment options, and understanding of new treatment options for MASH among providers remain limited. We aimed to assess the impact of targeted education for providers in the U.S. Methods: CLDF, GNC, and GHAPP members developed the MASH Educational Alliance Program (MEAP). Specifically, the content for the MEAP was created by faculty and underwent continuing medical education (CME) accreditation. From April 2024 to March 2025, a national live CME education initiative focusing on screening, diagnosing, and managing MASH was conducted for gastroenterologists and advanced practice providers (APPs). The initiative comprised 290 national live events. The course assessed outcomes at Moore’s Levels 1 (Participation) and 2 (Satisfaction). CE Outcomes and MASH Alliance collaborated on an outcomes study based on key performance measurements within the various initiatives to assess the attendees’ Levels 3 and 4 (Knowledge and Competence). A sample of learners completed a 30-day follow-up assessment, and the results were compared to those of a demographically matched control group who did not engage in the activities to understand lasting educational effects and how they apply the information in their practices (Level 5 – Performance). Results: A total of 5,322 learners participated. The following reflects significant knowledge and competence improvements analyzed by comparing a sample of learners to a non-learner control group.
·Learners post-education were more likely to recognize the global prevalence of MASLD at 38% (p < .001) and identify FIB-4 as the most recommended non-invasive test than pre-test scores (p < .001).
·Learners were likelier to appropriately diagnose a simulated patient with MASH/MASLD (p = .027) and to initiate treatment in a patient with MASH (p = .009).
·98% of learners reported that MEAP has helped them address key barriers in their practice.
·Learners were more familiar with clinical trials managing patients with NASH/MASH, specifically the MAESTRO-NASH and ESSENCE trials.
Discussion: A multifaceted and targeted educational program (MEAP) significantly improved gastroenterologists' and APPs' knowledge of MASH in clinical practice.
Figure: Figure
Disclosures: Zobair Younossi: Zobair M. Younossi is a consultant or has received research funding from Intercept, Cymabay, Boehringer Ingelheim, Ipsen, Gilead Sciences, Inventiva, – Consultant. Marcelo Kugelmas: Madrigal – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Novo Nordisk – Advisory Committee/Board Member, Speakers Bureau. Kimberly Brown: Intercept, Gilead, Salix, Ipsen, Madrigal – Advisor or Review Panel Member, Advisory Committee/Board Member, Speakers Bureau. Mallinckrodt – Advisory Committee/Board Member. Mallinckrodt – Advisory Committee/Board Member, Speakers Bureau. Mallinckrodt – Speakers Bureau. Christina Hanson: Ardelyx – Speakers Bureau. GSK – Speakers Bureau. Intercept – Speakers Bureau. Ipsen – Speakers Bureau. Madrigal – Speakers Bureau. Novo Nordisk – Speakers Bureau. Phathom – Speakers Bureau. Salix pharmaceuticals – Speakers Bureau. Sanofi/Regeneron – Speakers Bureau. Christina Hanson indicated no relevant financial relationships. Brian Lam: Madrigal – Advisor or Review Panel Member, Speakers Bureau. Fatema Nader indicated no relevant financial relationships. Samantha Scalici indicated no relevant financial relationships. Gregory Salinas indicated no relevant financial relationships. Christa Perry indicated no relevant financial relationships.
Zobair Younossi, MD, MPH1, Marcelo Kugelmas, MD1, Kimberly A.. Brown, MD2, Christina J. Hanson, FNP-C3, Christina Hanson, MD4, Brian Lam, PA-C1, Fatema Nader, MBBS1, Samantha H.. Scalici, MBA5, Gregory D. Salinas, PhD6, Christa Perry, MS7. P3698 - The MASH Educational Alliance Program Led to Significant Knowledge Improvement Among Front-Line Providers in the United States, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
